Fennec Pharmaceuticals Q2 2024 GAAP EPS $(0.20) Misses $(0.03) Estimate, Sales $7.262M Miss $11.049M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fennec Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.20), missing the estimate of $(0.03). Sales were $7.262 million, falling short of the $11.049 million estimate.
August 13, 2024 | 10:06 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Fennec Pharmaceuticals reported a significant earnings miss for Q2 2024, with GAAP EPS of $(0.20) missing the $(0.03) estimate and sales of $7.262 million missing the $11.049 million estimate.
The significant miss on both EPS and sales estimates is likely to negatively impact Fennec Pharmaceuticals' stock price in the short term. Investors typically react unfavorably to such earnings reports.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100